Efficacy and Safety between Insulin Glargine Products (LY2963016 and Lantus®) in Patients with T2DM: The ELEMENT 5 Study

被引：0

|

作者：

Pollom, Robyn K.

Lacaya, Lyndon B.

Ilag, Liza L.

机构：

来源：

DIABETES | 2017年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

963-P

引用

收藏

页码：A249 / A249

页数：1

相关论文

共 50 条

[41] Efficacy and safety of insulin glargine added to ongoing therapy with multiple oral antidiabetic drugs (OADs) in patients with type 2 diabetes mellitus (T2DM)
Davidson, Mayer B.
Raskin, Philip
Tanenberg, Robert
Vlajnic, Aleksandra
Hollander, Priscilla
DIABETES, 2007, 56 : A542 - A542
[42] Canagliflozin review - safety and efficacy profile in patients with T2DM
Jakher, Haroon
Chang, Tara I.
Tan, Marilyn
Mahaffey, Kenneth W.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 209 - 215
[43] Safety and efficacy comparison of different insulin regimens in T2DM patients: A meta-analysis
Gao, Xueying
Cai, Xiaoling
Yang, Wenjia
Ji, Linong
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S197 - S197
[44] The Long-Term Efficacy and Safety of Canagliflozin in Combination with Insulin in Japanese Patients with T2DM
Harashima, Shinichi
Inagaki, Nobuya
Kaku, Kohei
Kondo, Kazuoki
Maruyama, Nobuko
Otsuka, Makiko
Kawaguchi, Yutaka
Watanabe, Yumi
Goda, Maki
Iijima, Hiroaki
DIABETES, 2017, 66 : A34 - A34
[45] Similar Intrapatient Blood Glucose Variability with LY2963016 and LantusA® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
Nishiyama, Hiroshi
Shingaki, Tomotaka
Suzuki, Yumi
Ilag, Liza L.
DIABETES THERAPY, 2018, 9 (04) : 1469 - 1476
[46] Physician beliefs in efficacy of insulin glargine (GLAR) are associated with glucose control in type 2 diabetes (T2DM)
Herman, W.
Zhang, Q.
Kennedy, L.
DIABETOLOGIA, 2006, 49 : 527 - 528
[47] Glycaemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study
Halter, J.
Kennedy, L.
Miller, M.
Herman, W.
DIABETOLOGIA, 2006, 49 : 602 - 603
[48] Glycemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study
Halter, Jeffrey B.
Kennedy, Laurence
Herman, William H.
Miller, Michael E.
DIABETES, 2006, 55 : A114 - A115
[49] Efficacy and Safety in Persons with T2DM Treated with Insulin Glargine Plus Thrice-Daily Insulin Glulisine: A Meta-analysis of Four Studies
Owens, David R.
Traylor, Louise
Landgraf, Wolfgang
Porcellati, Francesca
Bolli, Geremia B.
DIABETES, 2015, 64 : A269 - A269
[50] New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs. Fixed Dosing Intervals in People with T2DM
Riddle, Matthew C.
Bolli, Geremia B.
Home, Phillip D.
Bergenstal, Richard
Ziemen, Monika
Muehlen-Bartmer, Isabel
Wardecki, Marek
Vinet, Laetitia
Yki-Jarvinen, Hannele
DIABETES, 2014, 63 : A235 - A235

← 1 2 3 4 5 →